Skip to content

Study · Case report or series · n = 1 · 2024

1 result

A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.

Le TTB, Minh LHN, Devi P, Islam N, Sachmechi I

Cureus1 Jan 2024Cited by 7 (Europe PMC)

PMID38298324 (opens in a new tab)PMCIDPMC10829695 (opens in a new tab)DOI10.7759/cureus.51460 (opens in a new tab)PepBankPUB-38298324
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

This report examines a case of systemic hypersensitivity to tirzepatide in a patient with type 2 diabetes. Tirzepatide (Mounjaro®), a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor, has recently gained FDA approval. Additionally, a literature review was conducted to summarize recent research on tirzepatide's effectiveness and safety. A 67-year-old woman, previously treated with basal insulin, metformin, and semaglutide (a GLP-1 agonist), experienced severe disseminated pruritus and a generalized urticarial rash after her first dose of tirzepatide. This reaction, which subsided with antihistamines, raises questions about possible immunoglobulin E-mediated hypersensitivity. The report highlights the need for increased vigilance regarding allergic reactions to new diabetes medications, particularly in the context of GIP/GLP-1 receptor agonists.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 67-year-old woman with type 2 diabetes had severe disseminated pruritus and a generalized urticarial rash after her first dose of tirzepatide, which subsided with antihistamines.

    In plain wordsOne woman with type 2 diabetes had an itchy whole-body rash after her first tirzepatide dose, which cleared with antihistamines.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSystemic allergic reaction after first dose
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    experienced severe disseminated pruritus and a generalized urticarial rash after her first dose of tirzepatide.
    2 context sentences
    Summary · context
    This reaction, which subsided with antihistamines, raises questions about possible immunoglobulin E-mediated hypersensitivity.
    Summary · context
    This report examines a case of systemic hypersensitivity to tirzepatide in a patient with type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.